{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:01:33Z","timestamp":1774987293986,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.dld.2018.09.012","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T20:24:28Z","timestamp":1537561468000},"page":"258-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is sofosbuvir\/ledipasvir safe for the hearts of children with hepatitis C virus?"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-7938","authenticated-orcid":false,"given":"Carolyne","family":"Ghobrial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodina","family":"Sobhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engy","family":"Mogahed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Abdullatif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanaa","family":"El-Karaksy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2018.09.012_bib0005","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4269\/ajtmh.2002.66.633","article-title":"Hepatitis C in a community in Upper Egypt: risk factors for infection","volume":"66","author":"Medhat","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.dld.2018.09.012_bib0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/jhep.2001.20797","article-title":"Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity","volume":"33","author":"Habib","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.012_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1478-3231.2010.02385.x","article-title":"Hepatitis C virus genotype 4 therapy: progress and challenges","volume":"31","author":"Kamal","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2018.09.012_bib0020","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/hep.22127","article-title":"Hepatitis C genotype 4: what we know and what we don\u2019t yet know","volume":"47","author":"Kamal","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.012_bib0025","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2008.11.006","article-title":"Ribavirin: current role in the optimal clinical management of chronic hepatitis C","volume":"50","author":"Reddy","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.012_bib0030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.012_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/HMER.S41127","article-title":"Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents","volume":"6","author":"Kamal","year":"2014","journal-title":"Hepat Med"},{"key":"10.1016\/j.dld.2018.09.012_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2015.0066","article-title":"Safety and efficacy of combined treatment with pegylated interferon alpha-2b and ribavirin for HCV genotype 4 in children","volume":"36","author":"El-Karaksy","year":"2016","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.dld.2018.09.012_bib0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for Study of Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.012_bib0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.09.012_bib0055","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2018.09.012_bib0060","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.09.012_bib0065","unstructured":"Food and Drug Administration FDA drug safety communication. FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug, http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm439484.htm. [Accessed 15 September 2016]."},{"key":"10.1016\/j.dld.2018.09.012_bib0070","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMc1505967","article-title":"Bradyarrhythmias associated with sofosbuvir treatment","volume":"373","author":"Fontaine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.09.012_bib0075","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1161\/01.CIR.67.6.1356","article-title":"Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations","volume":"67","author":"Kuo","year":"1983","journal-title":"Circulation"},{"key":"10.1016\/j.dld.2018.09.012_bib0080","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jelectrocard.2008.07.030","article-title":"The meaning of the Tp-Te interval and its diagnostic value","volume":"41","author":"Kors","year":"2008","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.dld.2018.09.012_bib0085","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.jacc.2005.12.049","article-title":"Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia\/ventricular fibrillation in patients with the Brugada syndrome","volume":"47","author":"Castro Hevia","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.dld.2018.09.012_bib0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jelectrocard.2011.03.004","article-title":"Assessment of repolarization heterogeneity for prediction of mortality in cardiovascular disease: peak to the end of the T wave interval and nondipolar repolarization components","volume":"44","author":"Smetana","year":"2011","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.dld.2018.09.012_bib0095","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart"},{"key":"10.1016\/j.dld.2018.09.012_bib0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/jcph.872","article-title":"Electrophysiological adverse effects of direct acting antivirals in patients with chronic hepatitis C","volume":"57","author":"Durante-Mangoni","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dld.2018.09.012_bib0105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1253\/jcj.62.389","article-title":"Hepatitis C virus infection and heart diseases: a multicenter study in Japan","volume":"62","author":"Matsumori","year":"1998","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.dld.2018.09.012_bib0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.510270106","article-title":"Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors","volume":"27","author":"Bernardi","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.012_bib0115","doi-asserted-by":"crossref","first-page":"15492","DOI":"10.3748\/wjg.v20.i42.15492","article-title":"Cirrhotic cardiomyopathy: a cardiologist\u2019s perspective","volume":"20","author":"Gassanov","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2018.09.012_bib0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1540-8167.2006.00622.x","article-title":"QT interval correction in patients with cirrhosis","volume":"18","author":"Zambruni","year":"2007","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.dld.2018.09.012_bib0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jelectrocard.2010.10.034","article-title":"Factors associated with a prolonged QT interval in liver cirrhosis patients","volume":"44","author":"Mozos","year":"2011","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.dld.2018.09.012_bib0130","first-page":"496","article-title":"Cirrhotic patients with Child-Pugh C have longer QT intervals","volume":"30","author":"Lanzieri","year":"2017","journal-title":"Int J Cardiovasc Sci"},{"key":"10.1016\/j.dld.2018.09.012_bib0135","first-page":"375","article-title":"Corrected QT interval and QT dispersion in cirrhotic patients before and after liver transplantation","volume":"15","author":"Zamirian","year":"2012","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.dld.2018.09.012_bib0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.mpg.0000228117.52229.32","article-title":"Hepatitis C in children: a quaternary referral center perspective","volume":"43","author":"Rumbo","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.dld.2018.09.012_bib0145","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/hep.22094","article-title":"Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial","volume":"47","author":"Goodman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.012_bib0150","series-title":"Product information: HARVONIR oral tablets, ledipasvir sofosbuvir oral tablets","author":"Gilead Sciences","year":"2015"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818309824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818309824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T20:32:57Z","timestamp":1548880377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865818309824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1590865818309824"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2018.09.012","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is sofosbuvir\/ledipasvir safe for the hearts of children with hepatitis C virus?","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2018.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}